Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for prevention of fractures in women with non-metastatic breast cancer receiving aromatase inhibitor therapy
2005-005275-15Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and osteoporosis comparing Denosumab with Placebo (2 arms). Primary endpoint: Time to first clinical fracture. Started Jun 2006; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancerosteoporosis
Beyond the preview
Go deeper on 2005-005275-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005275-15.